分享至
来源：金融界网
泽璟制药公告，公司近日收到国家药监局核准签发的《临床试验受理通知书》，ZG005粉针剂用于治疗实体瘤患者的临床试验申请获得受理。
特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布，本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
